Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €105.93 EUR
Change Today +2.46 / 2.37%
Volume 2.5K
CG3 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 2:19 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

celgene corp (CG3) Snapshot

Open
€104.00
Previous Close
€103.47
Day High
€106.17
Day Low
€104.00
52 Week High
03/20/15 - €119.90
52 Week Low
07/9/14 - €58.46
Market Cap
84.0B
Average Volume 10 Days
2.5K
EPS TTM
--
Shares Outstanding
793.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELGENE CORP (CG3)

celgene corp (CG3) Related Businessweek News

View More BusinessWeek News

celgene corp (CG3) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML). The company’s products also include THALOMID for the patients with multiple myeloma and for the treatment of cutaneous manifestations of erythema nodosum leprosum; OTEZLA for psoriatic arthritis, psoriasis, and ankylosing spondylitis; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its clinical stage products comprise oral anti-inflammatory agents targeting PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486 to treat MDS, AML, and solid tumors; Sotatercept and luspatercept for the treatment of anemia; and CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; MorphoSys AG; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; and NantBioScience, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

6,012 Employees
Last Reported Date: 02/20/15
Founded in 1980

celgene corp (CG3) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.4M
President and Chief Operating Officer
Total Annual Compensation: $767.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $400.0K
Chief Executive Officer of Celgene Cellular T...
Total Annual Compensation: $666.5K
President of Global Hematology and Oncology
Total Annual Compensation: $803.3K
Compensation as of Fiscal Year 2014.

celgene corp (CG3) Key Developments

Celgene and Juno Therapeutics Announce Ten-Year Collaboration to Advance Potentially Groundbreaking Immunotherapies for Patients with Cancer and Autoimmune Diseases

Celgene Corporation and Juno Therapeutics Inc. announced a global collaboration for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, including Juno’s CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen (BCMA) is excluded as a target in this collaboration. For Juno-originated programs co-developed under the collaboration: Juno will be responsible for research and development in North America and will retain commercialization rights in those territories; Celgene will be responsible for development and commercialization in the rest of the world, and will pay Juno a royalty on sales in those territories; and Celgene has certain co-promotion options: Celgene will initially be eligible to select two programs, excluding CD19 and CD22, to be subject to a global profit sharing agreement under which the companies will share worldwide expenses and profits equally, except in China; and additionally, subject to additional obligations, Celgene may select a third program. The parties will share global costs and profits with 70% allocated to Celgene and 30% allocated to Juno; and Celgene will lead global development and commercialization, subject to a Juno co-promote option in the US and certain EU territories. Upon closing, Juno will receive an upfront payment of approximately $150 million, and in addition Celgene will purchase 9,137,672 shares of Juno’s common stock at $93.00 per share.

Celgene Corporation, Juno Therapeutics Inc. - Special Call

To discuss collaboration for the development and commercialization of immunotherapies

Lycera and Celgene Partner to Advance Development of Immune Modulators

Lycera has entered an exclusive strategic collaboration with Celgene to advance the development of its proprietary pipeline for cancer and immune-mediated diseases. The partnership will advance development of Lycera's novel pipeline, including first-in-class RORgamma agonists for cancer immunotherapy and clinical-stage candidate, LYC-30937, being studied for inflammatory bowel disease (IBD). As part of the deal, Lycera will provide an $82.5 million upfront cash payment, which comprises an exclusive option for Celgene to license Lycera's portfolio of ex-vivo RORgamma agonist compounds. The deal will also allow Lycera to receive near term payments of an additional $22.5 million associated with the ex-vivo licensing option rights. In addition, the deal provides Celgene exclusive rights to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CG3:GR €105.93 EUR +2.46

CG3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Inc $405.41 USD +1.47
Bristol-Myers Squibb Co $67.67 USD +1.13
Eli Lilly & Co $84.85 USD +1.36
Shire PLC 5,210 GBp +115.00
Valeant Pharmaceuticals International Inc C$277.47 CAD +4.61
View Industry Companies
 

Industry Analysis

CG3

Industry Average

Valuation CG3 Industry Range
Price/Earnings 39.5x
Price/Sales 11.5x
Price/Book 13.6x
Price/Cash Flow 34.1x
TEV/Sales 9.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.